Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.
119 patients were enrolled in a double-blind randomized parallel study versus placebo carried out to assess both the efficacy and tolerability of L-deprenyl (10 mg/day) for treatment of patients with organic mental disorders of the Alzheimer type (DAT). The treatments were given for 3 months, starting after a run-in period of 15 days to evaluate efficacy. A complete neuropsychological battery was administered monthly after the start of treatment whereas tolerability was assessed by checking, recording and classifying all the unfavorable experiences occurring. According to the results, L-deprenyl would seem to be a useful and reliable tool for the treatment of DAT patients in an attempt to improve their cognitive functions and reduce behavioral alterations, without frequent or severe side effects.
Mangoni
A
A
Third Clinic of Neurology, University of Milan, Italy.
Grassi
M P
MP
Frattola
L
L
Piolti
R
R
Bassi
S
S
Motta
A
A
Marcone
A
A
Smirne
S
S
D000203:Activities of Daily Living; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011379:Prognosis; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*
D012642:Selegiline